Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance

Purpose: Rituximab was recently approved for use in relapsed, low-grade non-Hodgkin's lymphoma; how ever, few data exist regarding the safety of this agent in patients with a high number of tumor cells in the blood. Methods and Results: After the observation at our institution of a rapid reduction of peripheral-blood tumor cells with associated severe pulmonary infusion-related toxicity in two patients with refractory hematologic malignancies, data on three additional cases were collected from physician-submitted reports of adverse events related to rituximab treatment. five patients with hematologic malignancies possessing a high number of blood tumor cells were treated with rituximab and developed rapid tumor clearance, The median age was 68 years (range, 26 to 78 years). Patients were diagnosed with B-cell prolymphocytic leukemia (n = 2), chronic lymphocytic leukemia (n = 2), or transformed non-Hodgkin's lymphoma (n = 1), All of these patients had bulky adenopathy or organomegaly. All five patients developed a unique syndrome of severe infusion-related reactions, thrombocytopenia, rapid decrement in circulating tumor cell load, and mild electrolyte evidence of tumor lysis, and all required hospitalization. in addition, one patient developed ascites, These events resolved, and four patients were subsequently treated with rituximab without significant complications, Conclusion: Rituximab administration in patients who have a high number of tumor cells in the brood may have an increased likelihood of severe initial infusion-related reactions, These data also suggest that rituximab may have activity in a variety of other lymphoid neoplasms, such as chronic lymphocytic leukemia and B-cell prolymphocytic leukemia. (C) 1999 by American Society of Clinical Oncology.